Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.
Claire Gallois(Université Paris Cité), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Steven R. Alberts(North Central Cancer Treatment Group), Jeffrey A. Meyerhardt(CancerCare), Qian Shi(Mayo Clinic), Aimery de Gramont(Institut Hospitalier Franco Britannique), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Caroline Kelly(Cancer Research UK), Takayuki Yoshino(University of Tsukuba), Eiji Oki(Kyushu University), Frank A. Sinicrope(Mayo Clinic in Arizona), Ioannis Sougklakos(University Hospital of Heraklion), Anthony F. Shields(Wayne State University), Demetris Papamichail(Bank of Cyprus Oncology Center), Thierry André(Inserm), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino), Daniel G. Haller(University of Pennsylvania), Jeffrey P. Meyers(Mayo Clinic in Florida), Ioannis Boukovinas
Cited by 8
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k